Wordt geladen...
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
BACKGROUND: TKIs are the first-line treatment for patients with Ph-positive (Ph+) leukemia. However, drug resistance is frequently observed, mainly due to mutations within the breakpoint cluster region-Abelson leukemia virus (BCR-ABL) kinase domain. The T315I substitution confers complete resistance...
Bewaard in:
| Gepubliceerd in: | Onco Targets Ther |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5626416/ https://ncbi.nlm.nih.gov/pubmed/29026321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S142482 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|